27.10.2022 |
EN |
Official Journal of the European Union |
C 412/9 |
Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))
(Text with EEA relevance)
(2022/C 412/06)
Decision granting an authorisation
Reference of the decision (2) |
Date of decision |
Substance name |
Holder(s) of the authorisation |
Authorisation number |
Authorised use |
Date of expiry of review period |
Reasons for the decision |
C(2022) 7381 |
20 October 2022 |
4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (4-tert-OPnEO) EC No: -, CAS No:- |
Merck KGaA, Frankfurter Strasse, 64293 Darmstadt, Germany |
REACH/22/34/0 |
As raw material for the manufacturing of GMP Triton® X-100 Emprove® Expert in accordance with International Pharmaceutical Excipients Council Europe standards |
4 January 2033 |
In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the uses of the substance and there are no suitable alternative substances or technologies. |
(1) OJ L 396, 30.12.2006, p. 1.
(2) The decision is available on the European Commission website at: Authorisation (europa.eu).